THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

References

• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909
   PubMed Web of Science ®Google Scholar
• Zeldenrust S. ATTR: diagnosis, prognosis and treatment. In: Gertz M, Rajkumar S, eds. Amyloidosis: Diagnosis and Treatment. New York, NY: Humana Press, Springer Science, Business Media LLC; 2010:191-204
   Google Scholar
• Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-16
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62
   PubMed Web of Science ®Google Scholar
• Pitkänen P, Westermark P, Cornwell GG 3rd. Senile systemic amyloidosis. Am J Pathol 1984;117:391-9
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000;51:543-69
   PubMed Web of Science ®Google Scholar
• Herrick MK, DeBruyne K, Horoupian DS, et al. Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 1996;47:988-92
   PubMed Web of Science ®Google Scholar
• Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003;60:1625-30
   PubMed Web of Science ®Google Scholar
• Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23
   PubMed Web of Science ®Google Scholar
• Hornsten R, Pennlert J, Wiklund U, et al. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010;17:63-8
   PubMed Web of Science ®Google Scholar
• Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73
   PubMed Web of Science ®Google Scholar
• Buxbaum J, Alexander A, Koziol J, et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 2010;159:864-70
   PubMed Web of Science ®Google Scholar
• Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J 1998;19:782-9
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-53
   PubMed Web of Science ®Google Scholar
• Ranlov I, Alves IL, Ranlov PJ, et al. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am J Med 1992;93:3-8
   PubMed Web of Science ®Google Scholar
• Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:512-21
   PubMed Web of Science ®Google Scholar
• Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-4
   PubMed Web of Science ®Google Scholar
• Coutinho P, Martins da Silva A, Kopes Lima J, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner G, Pinho e Costa P, Folcao de Freitas A, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica, 1980:88-98
   Google Scholar
• Araki S, Kurihara T, Tawara S, et al. Familial amyloidotic polyneuropathy in Japanese. In: Glenner G, Pinho e Costa P, Folcao de Freitas A, eds. Amyloid and Amyloidosis. Portugal: Excerpta Medica, 1980:67-77
   Google Scholar
• Ando Y, Araki S, Ando M. Transthyretin and familial amyloidotic polyneuropathy. Intern Med 1993;32:920-2
   PubMed Web of Science ®Google Scholar
• Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994;235:479-85
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Said G. Transthyretin related familial amyloid polyneuropathy. Curr Opin Neurol 2000;13:569-73
   PubMed Web of Science ®Google Scholar
• Mörner S, Hellman U, Suhr OB, et al. Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med 2005;258:225-30
   PubMed Web of Science ®Google Scholar
• Engvall C, Henein M, Holmgren A, et al. Can myocardial strain differentiate hypertrophic from infiltrative etiology of a thickened septum? Echocardiography 2011;28:408-15
   PubMed Web of Science ®Google Scholar
• EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208
   Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005;7:497-508
   PubMedGoogle Scholar
• Vinik EJ, Vinik AI, Paulson JF, et al. Validation of Norfolk QOL-DN as a measure of QOL in patients with transthyretin familial amyloid polyneuropathy. Presented at the 2011 Peripheral Nerve Society Biennial Meeting, Maryland, MD, USA, 2011
   Google Scholar
• Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49
   PubMed Web of Science ®Google Scholar
• Hattori T, Takei Y, Koyama J, et al. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid 2003;10:229-39
   PubMed Web of Science ®Google Scholar
• Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-7
   PubMed Web of Science ®Google Scholar
• Suhr OB, Lindqvist P, Olofsson BO, et al. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 2006;13:154-9
   PubMed Web of Science ®Google Scholar
• Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002;59:1771-6
   PubMed Web of Science ®Google Scholar
• Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand 1976;198 (Suppl 590):1-64
   Google Scholar
• Soares M, Buxbaum J, Sirugo G, et al. Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Hum Genet 1999;104:480-5
   PubMed Web of Science ®Google Scholar
• Drugge U, Andersson R, Chizari F, et al. Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis. J Med Genet 1993;30:388-92
   PubMed Web of Science ®Google Scholar
• Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-6
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ikeda S, Hanyu N, et al. A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy. J Med Genet 1998;35:23-30
   PubMed Web of Science ®Google Scholar